Guerbet : Feedback réunion d’analystes et relèvement de notre objectif de cours à 39 € vs 29 €
>Séquence de rebond (quasi historique) de la croissance - En guidant sur une croissance d’au moins 8%e en 2024, Guerbet rompt avec plusieurs années de croissance modeste. Sur les 12 derniers exercices, Guerbet n’a dépassé qu’une seule fois le seuil des 8%. Ce niveau serait permis par la conjonction de plusieurs phénomènes : 1/ depuis 12 mois, Guerbet arrive à passer des hausses de prix, sur les Rayons-X (55% du CA), chose que nous n’avions pas vu depuis plus de 10 ans...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.